In vitro tumor cell-binding assay to select high-binding antibody and predict therapy response for personalized 64Cu-intraperitoneal radioimmunotherapy against peritoneal dissemination of pancreatic cancer.

Fukiko Hihara

[WP-28-7] In vitro tumor cell-binding assay to select high-binding antibody and predict therapy response for personalized 64Cu-intraperitoneal radioimmunotherapy against peritoneal dissemination of pancreatic cancer.

Fukiko Hihara¹、Hiroki Matsumoto^1,4、Takashi Masuko²、Yuichi Endo Endo²、Chika Igarashi¹、Tomoko Tachibana¹、Gene Kurosawa³、Aya Sugyo¹、Atsushi B. Tsuji Tsuji¹、Yukie Yoshii¹ (1.National Institutes for Quantum Science and Technology、2. School of Pharmacy, Kindai University、3.International Center for Cell and Gene Therapy, Fujita Health University、4.Department of Diagnostic Radiology, Kanagawa Cancer Center)

抄録パスワード認証
パスワードは「総合プログラム集」の151ページに記載してあります。

講演情報

Nuclear Medicine Innovation1

Therapy

[WP-28-7] In vitro tumor cell-binding assay to select high-binding antibody and predict therapy response for personalized 64Cu-intraperitoneal radioimmunotherapy against peritoneal dissemination of pancreatic cancer.

パスワード